

Choledyl reduces invalidism in chronic bronchitis and asthma by relaxing bronchospasm : garganey.

Contributors

Allen & Hanburys

Publication/Creation

London : Allen & Hanburys, 1966.

Persistent URL


<https://wellcomecollection.org/works/qwmmxnes>

License and attribution

Conditions of use: it is possible this item is protected by copyright and/or related rights. You are free to use this item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).



Wellcome Collection
183 Euston Road
London NW1 2BE UK
T +44 (0)20 7611 8722
E library@wellcomecollection.org
<https://wellcomecollection.org>



CARGANEY.

To the Medical Profession

CHOLEDYL

Trade Mark

reduces invalidism in
chronic bronchitis and
asthma by relaxing
bronchospasm

CHOLEDYL*

- provides a higher degree of effectiveness than oral aminophylline
- is well tolerated
- remains effective during prolonged administration
- reduces the risk of gastric irritation

INDICATION

for relief and prevention of bronchospasm.

DOSAGE

Adults: 0.6 gramme to 1.6 gramme daily, in divided doses.

Children: over 6 years: 300 mg to 400 mg daily, in divided doses.

Under 6 years: Choleldyl should be administered in the form of

Choleldyl Syrup:— under 1 year: 7.5 mg per 1lb body weight daily, in divided doses. 1 to 3 years: 150 mg to 225 mg daily, in divided doses.

3 to 6 years: up to 300 mg daily, in divided doses.

In all cases Choleldyl should be taken after a meal.

PRESENTATION

Choleldyl is available in tablets containing 100 mg or 200 mg choline theophyllinate BP, in bottles of 100 and 500 and as a syrup containing 50 mg choline theophyllinate BP in each teaspoonful (4ml) in bottles of 114 ml (4 fl ozs) and 2 litres.

The basic NHS cost for a bottle of 100 tablets is 9/4d for the 100 mg strength, 12/- for the 200 mg strength and 6/- for a bottle of Choleldyl Syrup.

Manufactured in England by ALLEN & HANBURYS LIMITED LONDON E2

*Under licence from Warner-Lambert Pharmaceutical Co., New Jersey, U.S.A., owners of the trade mark and patents.

Patents granted: India, 50,707; R. of S. Africa, 22,325; U.K., 736,443.